# 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients

> **NCT01948791** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 222 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** ENA713

## Key facts

- **NCT ID:** NCT01948791
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2017-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01948791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01948791, "16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01948791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*